Sumitomo Chemical India Limited has informed the Exchange about Transcript
SUMICHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sumitomo Chemical India reported Q2 FY26 consolidated revenue of INR930 crores, down from INR988 crores in Q2 FY25, due to excessive and prolonged rainfall during July-September that disrupted Kharif spraying operations. Despite the seasonal weakness, H1 FY26 revenue grew 9% YoY to INR1,987 crores with PAT up 11% at INR356 crores. EBITDA margin held at 22% in H1 (vs 22.2% last year), and gross margin improved to 43.1% in Q2 from 42.6% earlier, with management stating they will maintain or improve margins going forward. Cash and equivalents stood strong at INR2,089 crores, and net working capital days improved by 7 days to 55 days. New product launches Excalia Max (fungicide) and Lentigo (rice herbicide) are tracking ahead of internal targets and being scaled up, while the company is evaluating deployment of INR500-600 crores over five years for a Dahej greenfield project. Subsidiary Barrix and the global semiconductor opportunity remain in early stages pending regulatory and customer readiness.
For shareholders, the transcript shows resilient H1 performance with double-digit profit growth despite a weather-hit quarter, no price cuts, and a strong balance sheet with INR2,089 crores in cash. The stock could find support from margin protection commentary and the robust Rabi outlook, though near-term sentiment may stay cautious until export recovery (particularly Brazil/Africa) and Dahej capex plans translate into visible execution.